logo
Plus   Neg
Share
Email

CureVac, Novartis Sign Initial Agreement For Manufacturing Of CureVac's COVID-19 Vaccine Candidate

CureVac N.V. (CVAC), and Novartis AG have signed an initial agreement for the manufacturing of CureVac's COVID-19 vaccine candidate, CVnCoV. Novartis plans to start manufacturing of the mRNA and bulk drug product of CureVac's COVID-19 vaccine candidate, CVnCoV, in the second quarter of 2021.

Following final agreement, Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. The delivery from the manufacturing site in Kundl, Austria, is expected to start in summer 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retail major Target Corp. is recalling about 44,350 units of Cat & Jack Baby Heart Ears Rompers, citing choking risks to children, the U.S. Consumer Product Safety Commission said in a statement. The recall involves rompers sold in various sizes from newborn to 24 months. The rompers were manufactured in Vietnam, and sold at Target stores across the United States and online. Alcoa Corp. (AA), the largest producer of aluminum in the US, Thursday reported a first-quarter profit that more than doubled from a year ago, driven by increased shipments and prices. Both adjusted earnings and revenues for the quarter trumped Wall Street analysts' estimates. Pittsburgh-based Alcoa... Walmart expects two-thirds of their Walmart U.S. hourly store roles to become full-time by the end of the current fiscal year, with consistent schedules from week to week, as part of their focus on creating even more opportunity for associates at Walmart.
Follow RTT